Locally advanced unresectable or metastatic androgen receptor positive triple negative breast cancer (or ER low HER2 negative breast cancer), progressive after at least 1 prior cytostatic regimen in advanced setting. If ER low additionally at least one line of endocrine therapy in advanced setting.

• A multicenter uncontrolled, open label, prospective non-comparative single arm phase II study with bicalutamide (an antiandrogen) in combina … Recruiting
  2022-502272-23-00 4 2024-04-08

Showing 1–1 of 1 trials